BERG Health is a clinical-stage, artificial intelligence (AI)-powered biotechnology company. They utilize their proprietary Interrogative Biology® platform, which combines patient biology and AI-based analytics, to develop novel therapeutics and diagnostics. BERG focuses on oncology, metabolic diseases, and rare diseases, aiming to understand disease mechanisms and identify new treatment targets. Their approach aims to accelerate drug discovery and development, leading to more personalized and effective treatments for complex diseases.
The Framingham headquarters serves as the core for BERG Health's research and development, AI platform operations, clinical development strategy, and corporate administration.
Features advanced laboratory facilities for biological research, high-performance computing infrastructure for AI and data analytics, and collaborative workspaces designed to foster innovation.
BERG Health fosters a work culture centered on scientific inquiry, innovation, and collaboration. Employees are driven by the mission to transform healthcare through AI and deep biological understanding, working in interdisciplinary teams.
Its location in the Boston biotech hub provides access to world-class talent, leading academic institutions, research partners, and a vibrant investment community, crucial for its pioneering work.
While headquartered in the United States, BERG Health's operational scope and impact are global. The company engages in international collaborations with research institutions, participates in global clinical trials to ensure diverse patient populations, and its AI-driven drug discovery platform processes data from worldwide sources. Their focus on diseases like cancer and neurological disorders addresses global health challenges, positioning them as a player in the international biopharmaceutical landscape.
500 Old Connecticut Path, Building B, 3rd Floor
Framingham
Massachusetts
USA
Address: Not publicly listed as permanent branch offices
These collaborations facilitate global clinical trials, diverse patient data acquisition, and access to specialized research expertise pertinent to BERG's drug development programs in oncology and neurology.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, BERG' leadership includes:
BERG has been backed by several prominent investors over the years, including:
Specific executive hires or departures at BERG Health are not frequently publicized outside of major announcements. Based on publicly available information from the last 12 months, there have been no widely reported significant changes to the core senior executive team. The company appears to maintain a stable leadership.
Discover the tools BERG uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
BERG Health likely employs standard corporate email address formats. The most common patterns for companies of its type include [first_initial][last_name]@berghealth.com or [first_name].[last_name]@berghealth.com.
[first_initial][last_name]@berghealth.com
Format
nnarain@berghealth.com (example for Niven Narain, based on presumed format)
Example
75%
Success rate
PR Newswire • December 5, 2023
BERG Health announced significant findings published in Nature Communications regarding an AI-discovered blood-based biomarker panel. This panel shows promise for the early detection of pancreatic cancer, potentially transforming diagnostic approaches for this challenging disease....more
PR Newswire • April 17, 2023
At the American Association for Cancer Research (AACR) Annual Meeting 2023, BERG Health presented compelling preclinical data for its lead therapeutic candidate, BPM 31510 (IV Ubidecarenone). The study demonstrated significant tumor growth inhibition in pancreatic cancer models, highlighting its potential as a future treatment....more
Business Wire • January 10, 2023
BERG Health secured a new U.S. patent for its innovative Interrogative Biology® platform. This patent further protects its AI-driven approach to identifying novel cancer biomarkers and therapeutic targets, reinforcing its leadership in AI-powered drug discovery....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including BERG, are just a search away.